Understanding Your Genetic and Pathology Reports

When your child is being evaluated for Blau syndrome, the two most important documents you will receive are the genetic testing report and the pathology (biopsy) report. These documents help doctors evaluate the evidence and support the diagnosis. Because this condition is so rare, understanding the specific terms in these reports can help you advocate for the most accurate care ^[1][2].

The Genetic ‘Instruction Manual’: NOD2 Mutations

Blau syndrome is associated with mutations in the NOD2 gene. This gene provides instructions for a protein that acts as a sensor in the immune system. In a healthy child, this sensor turns “on” to fight bacteria and “off” when the threat is gone. In Blau syndrome, a gain-of-function mutation means the sensor is permanently stuck in the “on” position, causing the body to create inflammation even when there is no infection ^[3][4].

Your report will likely list a specific “variant” or change in the DNA code. Some non-exhaustive examples of common pathogenic (disease-causing) variants include:

• p.Arg334Trp (often written as R334W) ^[1][5]
• p.Arg334Gln (R334Q) ^[1][6]
• p.Glu383Lys, p.Gly481Asp, and p.Trp490Ser ^[1]

If your report lists a Variant of Uncertain Significance (VUS), it means the lab found a change but isn’t sure yet if it causes the disease. A VUS should not be treated as a disease-causing result or used alone for predictive family decisions. In these cases, doctors must look closely at your child’s symptoms and biopsy results to decide if the variant is truly the cause ^[7][1].

Understanding Inheritance and Mosaicism

An affected individual with a confirmed pathogenic autosomal-dominant variant may have a 50% chance of passing it to each child. Most cases of Blau syndrome appear to be “de novo,” meaning the mutation started with the child and neither parent has it in their blood ^[8][6]. However, the recurrence risk for unaffected parents is usually low but not zero because of possible gonosomal mosaicism. This means a parent carries the mutation in only a small percentage of their cells—including their reproductive (germ) cells—but not enough to show symptoms themselves or show up on a standard test ^[9]. Because of this, medical teams recommend genetic counseling for parents and siblings to discuss the risks for future children ^[9][10].

The Tissue Evidence: What a Skin Biopsy Shows

A skin biopsy involves taking a small sample of a rash or lump to look at it under a microscope. The pathologist is looking for granulomas, which are tight balls of immune cells. In Blau syndrome, these have specific features:

• Non-caseating (or Non-necrotizing): This means the center of the immune cell cluster is solid and “clean,” rather than having “cheesy” dead tissue (necrosis) in the middle. The absence of necrosis does not rule out infection, and negative AFB, GMS, or PAS stains have limited sensitivity. Cultures, PCR, exposure history, and specialist assessment may be needed before immunosuppression ^[2][11].
• “Naked” Granulomas: Pathologists use this term when the clusters of immune cells are “naked”—meaning they aren’t surrounded by a thick ring of other inflammatory cells (lymphocytes) ^[12][13].
• Multinucleated Giant Cells: These are large cells formed when several immune cells fuse together. They are a classic hallmark of the granulomas seen in this condition ^[11][12].

Biopsy depth should match the lesion and the clinical question; a typical superficial granulomatous rash does not require a deep panniculitis specimen ^[2].

Completeness Checklist for Your Reports

When you receive your child’s reports, check for these key elements. If they are missing, you can ask your doctor for a more detailed “addendum” or a second look by a specialist.

Genetic Report Checklist:

• [ ] Specific Variant Name: Is it written in standard “HGVS” format (e.g., c.1000C>T, p.Arg334Trp)? ^[7]
• [ ] Classification: Is the variant labeled as Pathogenic, Likely Pathogenic, or a VUS? ^[1]
• [ ] Transcript Number: Does it list the reference code (e.g., NM_022162.3) for the NOD2 gene? ^[7]
• [ ] Zygosity: Does it state “Heterozygous” (meaning one copy of the gene is mutated)? ^[7]

Pathology Report Checklist:

• [ ] Description of Granulomas: Does it describe the granulomas as “non-caseating” or “non-necrotizing”? ^[2][11]
• [ ] Infectious Stains: Does the report mention results for acid-fast bacilli (AFB) and fungal (GMS/PAS) stains, knowing a negative stain is not the same as a guaranteed negative infection test? ^[14][15]
• [ ] Clinical Correlation: Pathologists generally report compatible findings and recommend clinical correlation rather than establish this diagnosis outright. Does the report state findings are compatible with a granulomatous disease? ^[2]